Fingolimod during pregnancy: Is it safe?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - May 8, 2014 Category: Consumer Health News Source Type: news
Novartis Receives CHMP Recommendation For Gilenya EU Label Expansion
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation to expand the EU label for Gilenya (fingolimod), an approved drug in the EU for adult patients with relapsing remitting multiple sclerosis (RRMS). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - May 1, 2014 Category: Pharmaceuticals Source Type: news
Fingolimod (Gilenya)
Trial data suggests that fingolimod reduces brain volume loss. Presented at the AAN conference.
Novartis press release
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 29, 2014 Category: Neurology Source Type: news
Fingolimod (Gilenya) licence extension recommended
A committee of the European Medicines Agency (EMA) has recommended the extension to the licensing of fingolimod (Gilenya) that would mean people can be prescribed the drug if they continue to have relapses despite treatment with at least one disease modifying therapy (previous this only applied after beta interferon treatment) .
EMA
Reuters
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 24, 2014 Category: Neurology Source Type: news
Fingolimod (Gilenya) licence extended
The European Medicines Agency (EMA) has approved an extension to the licensing of fingolimod (Gilenya), meaning that people can be prescribed the drug if they continue to have relapses despite treatment with at least one disease modifying therapy (previous this only applied after beta interferon treatment) .
EMA
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 24, 2014 Category: Neurology Source Type: news
Shorter Washout Better for Natalizumab-to-Fingolimod Switch Shorter Washout Better for Natalizumab-to-Fingolimod Switch
A new study further confirms that upon switching from natalizumab to fingolimod in patients with multiple sclerosis, the washout period should be less than 3 months. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 26, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Fingolimod in MS: Long-Term Efficacy and Brain Volume Data Fingolimod in MS: Long-Term Efficacy and Brain Volume Data
Other data from the fingolimod clinical trial program add to evidence that brain volume loss correlates with long-term disability. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
FDA Investigates Brain Infection-Gilenya Case
WebMD Health News
By Kathleen Doheny
Reviewed by Michael W. Smith, MD
Oct. 18, 2013 — The FDA is continuing to investigate a possible link between the multiple sclerosis drug Gilenya (fingolimod) and a case of a rare brain infection in a European patient.
The patient took the drug for nearly 8 months before being diagnosed with the brain infection. The FDA issued an alert at the end of August to inform the public of its investigation.
The brain infection, sometimes fatal, is called PML (progressive multifocal leukoencephalopathy). The European case is the first reported in a patient who has not previously taken the d...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 23, 2013 Category: Consumer Health News Authors: mreal197 Tags: WebMD News Source Type: news
FDA Investigates Brain Infection-Gilenya Case
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 21, 2013 Category: Journals (General) Source Type: news
FDA Investigates Brain Infection-Gilenya Case
The FDA is continuing to investigate a possible link between the multiple sclerosis drug Gilenya (fingolimod) and a case of a rare brain infection in a European patient. (Source: WebMD Health)
Source: WebMD Health - October 18, 2013 Category: Consumer Health News Source Type: news
From Copenhagen, an Update on FingolimodFrom Copenhagen, an Update on Fingolimod
New data presented at ECTRIMS 2013 offer guidance on how to best use fingolimod in multiple sclerosis. Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news
Fingolimod (Gilenya) at ECTRIMS
An American neurologist reviews the range of information about fingolimod presented at the recent ECTRIMS conference.
Medscape (requires free registration)
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - October 14, 2013 Category: Neurology Source Type: news
Parkinson's drug could prove to be new treatment for multiple sclerosis
Early tests show that benztropine stimulates the production of nerve-repairing cells and helped eliminate MS relapsesA drug used to treat Parkinson's disease may provide an effective new therapy for multiple sclerosis (MS), research suggests.Early tests on mice show that benztropine stimulates the production of nerve-repairing cells.Scientists hit on the drug after screening 100,000 compounds for their abilitly to trigger the development of cells that rebuild damaged myelin, the protective fatty sheath that surrounds nerve fibres.MS is an autoimmune disease that causes the body's defences to attack myelin, causing symptoms...
Source: Guardian Unlimited Science - October 9, 2013 Category: Science Tags: theguardian.com News Medical research Society Multiple sclerosis Parkinson's disease Science Source Type: news
Shorter Washout Reduces MS Relapse Switching Off NatalizumabShorter Washout Reduces MS Relapse Switching Off Natalizumab
New data suggest that relapse rate can be kept low with washout period of 8 weeks or less when switching from natalizumab to fingolimod. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 7, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
